Actelion files new PAH treatment Uptravi
This article was originally published in Scrip
Executive Summary
Actelion has made its first regulatory filing for its novel treatment for pulmonary arterial hypertension (PAH), selexipag, in the EU as Uptravi. Further submissions, including to the US FDA, are "forthcoming", it said.